Shek L L, Godolphin W
Department of Pathology, University of British Columbia, Vancouver, Canada.
Eur J Cancer Clin Oncol. 1989 Feb;25(2):243-50. doi: 10.1016/0277-5379(89)90015-1.
The survival of 1184 British Columbian women whose primary breast cancers were diagnosed and assayed for estrogen receptor (ER) between 1975 and 1981 was studied. Median follow-up was 60 months. ER concentrations yielded greater prognostic information than simple positive and negative categories. When ER data were divided into four strata: less than or equal to 1, 2-9, 10-159 and greater than or equal to 160 fmol/mg cytosol protein, the association of higher ER with prolonged survival was highly significant (P less than 0.0001) and independent of TNM stage, nodal status and menopausal status. ER less than or equal to 1 and ER = 2-9 groups were distinct with respect to overall disease-specific survival. Patient age did not predict survival when controlled for ER. Prolonged recurrence-free survival was associated with higher ER (P = 0.0001) for at least 5 years after diagnosis. This significant trend persisted after adjustments for nodal status, TNM stage, menopausal status and the type of systemic adjuvant therapy.
对1975年至1981年间确诊并检测雌激素受体（ER）的1184名不列颠哥伦比亚省女性原发性乳腺癌患者的生存情况进行了研究。中位随访时间为60个月。与简单的阳性和阴性类别相比，ER浓度提供了更多的预后信息。当将ER数据分为四个层次：小于或等于1、2 - 9、10 - 159以及大于或等于160 fmol/mg胞浆蛋白时，较高的ER与较长生存期的关联非常显著（P小于0.0001），且独立于TNM分期、淋巴结状态和绝经状态。ER小于或等于1和ER = 2 - 9的组在总体疾病特异性生存方面有所不同。在控制ER后，患者年龄不能预测生存情况。诊断后至少5年，较长的无复发生存期与较高的ER相关（P = 0.0001）。在对淋巴结状态、TNM分期、绝经状态和全身辅助治疗类型进行调整后，这一显著趋势仍然存在。
